JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes - Rumi, E; Pietra, D; Ferretti, V; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. (Blood, 2014)